Comparison of recombinant human PTH(1-34) (LY333334) with a C-terminally substituted analog of human PTH-Related protein (1-34) (RS-66271): In vitro activity and in vivo pharmacological effects in rats

Parathyroid hormone (PTH) and PTH-related protein (PTHrP) are believed to exert their biological actions through binding and activation of a common cell surface receptor, Recently, an analog of PTHrP (RS-66271), was described that demonstrated reduced binding affinity for the PTH/PTHrP receptor compared with bovine PTH(1-34) but retained equal biological activity. The present study investigated the receptor binding affinities of synthetic RS-66271 and recombinant human PTH(1-34) (LY333334) and compared their in vitro and in vivo pharmacological effects, RS-66271 had one hundredth the activity of PTH(1-34) in competing for the binding of [I-125][Nle(8,18) Tyr(34)]human PTH(1-34) to the human PTH/PTHrP receptor stably expressed in a human kidney cell line. Despite this: reduced binding affinity, RS-66271 had equivalent activity in increasing both cAMP production in osteoblastlike cells and bone resorption in neonatal mouse calvariae, However, RS-66271 was 7.6-fold less active in stimulating inositol phosphate production. For in vivo studies, young, male Fisher rats received a daily subcutaneous dose of either 10 or 40 mu g/kg of peptide for 1, 2, or 4 weeks, Volumetric bone mineral density and total bone mineral content of the proximal tibia were determined by peripheral quantitative computerized tomography, Trabecular and cortical bone of the distal femur were analyzed for calcium and dry weight, Lumbar vertebrae (A4-L6) were analyzed by histomorphometry, Trabecular and cortical bone mass showed a dose- and time-dependent increase in the treated animals compared with the controls, These increases were evident as early as 1 week after initiation of dosing. There were no consistent significant differences in the comparative effects of PTH(1-34) and RS-66271 on the measured bone parameters, In conclusion, despite the reduced binding affinity of RS-66271 for the PTH/ PTHrP receptor compared with human PTH(1-34), both peptides displayed similar in vitro and in vivo pharmacological effects.